Virtual Investor Day to discuss positive results from Phase 2b Study of Istaroxime in early cardiogenic shock to be held on October 1 at 3 pm. Webcast Link
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WINT:
- Windtree Therapeutics Updates Investor Presentation Materials
- Windtree Therapeutics announces Phase 2b topline results of istaroxime
- Windtree Therapeutics announces topline results from 2b SEISMiC Extension Study
- Windtree Therapeutics Expands Stock and Restructures Finances
- Windtree Therapeutics completes enrollment of Phase 2b study of istaroxime